Latest Orphan drugs Stories
Expects to complete submission in the first half of 2015 DUBLIN, Dec.
SAN DIEGO, Dec.
DALLAS, December 9, 2014 /PRNewswire/ -- RnRMarketResearch.com adds "Gaucher's Disease - Pipeline Review, H2 2014" market research report of 74 pages with an overview of
APTO-253 In Vivo Data Demonstrate Single-Agent and Combination Activity in AML SAN FRANCISCO, CA, Dec. 9, 2014 /PRNewswire/ - Aptose Biosciences Inc.
Follow-up data from the Phase 2 PCYC-1104 trial presented at the American Society of Hematology Annual Meeting show sustained efficacy and safety over time SAN FRANCISCO and RARITAN, N.J.,
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
- Fewer patients on Tasigna vs. Gleevec had their leukemia progress to advanced stage, a key goal of treatment in CML and important clinical benefit (1) EAST HANOVER, N.J., Dec.
Company Outlines Plans for Phase III Registration Study San Diego, Dec. 8, 2014 /PRNewswire/ -- MEI Pharma, Inc.
Interim Data from 33 Evaluable Patients to be Presented at ASH on Saturday SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc.
PORTLAND, Oregon, December 2, 2014 /PRNewswire/ -- GBI Research, the leading business intelligence provider, has released its latest research, "Glioblastoma Multiforme
- A transitional zone between two communities containing the characteristic species of each.